Press release
May 5, 2026
Electra Therapeutics Announces First Patient Dosed in Phase 1 Study of Ipsoprubart (ELA026) in T Cell Malignancies
Electra Therapeutics, Inc. (ETRA)
SOUTH SAN FRANCISCO, CA, May 5, 2026 – Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced dosing of the first patient in a Phase 1 study of ipsoprubart (ELA026) in patients with T cell